Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Medi-Caps has informed that the United States Food & Drug Administration (USFDA) conducted a GMP inspection of the manufacturing facility of Wholly Owned Subsidiary Company, Medgel at Pithampur, Madhya Pradesh from 17th February to 21st February 2025. At the conclusion of the inspection on 21st February 2025, Form 483 was issued to the company. The company has clarified that there were no observations related to data integrity, and all the observations were procedural in nature. The company will work in close collaboration with the agency to address the observations and will respond to the USFDA within stipulated timeline. The above information will also be available on the website of the Company at www.medicaps.com.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| BASF India | 3653.10 |
| Tata Chemicals | 704.05 |
| SRF | 2464.40 |
| Pidilite Inds. | 1390.15 |
| Deepak Nitrite | 1537.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: